Quantitative assessment of late lumen loss after biodegradable polymer and permanent polymer sirolimus-eluting stents implantation

Chinese Medical Journal

Volumn 126, Issue 6, 2013, Pages 1081-1085

  Kan, Jing ^a,b   Chen, Feng ^b   Liu, Li Ya ^b   Xu, Hai Mei ^a   Lin, Ling ^a   Liu, Yan ^a   Zhao, Ying Ying ^a   Cheng, Jiu Pei ^c   Chen, Shao Liang ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c Department of Cardiology   (China)

Author keywords

Coronary artery disease; Drug eluting stent; Late lumen loss; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; RAPAMYCIN;

AGED; ANGIOGRAPHY; ARTICLE; BARE METAL STENT; BLOOD VESSEL DIAMETER; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; LATE LUMEN LOSS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; STENOSIS;

AGED; ASPIRIN; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMERS; REGRESSION ANALYSIS; SIROLIMUS; TICLOPIDINE;

EID: 84876935316     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20123385     Document Type: Article

References (24)

1. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003; 108: 788-794.
2. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. NEnglJ Med 2003; 349: 1315-1323.
3. Xu B, Dou KF, Yang YJ, Chen JL, Qiao SB, Wang Y, et al. Comparison of long-term clinical outcome after successful implantation of FIREBIRD and CYPHER sirolimus-eluting stents in daily clinical practice: analysis of a large single-center registry. Chin Med J 2011; 124: 990-996.
4. Wang CH, Fang Q, Zhang SY, Shen ZJ, Fan ZJ, Jin XF, et al. Long-term effects of drug-eluting stents versus bare metal stents on patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: outcomes of 3-year clinical follow-up. Chin Med J 2012; 125: 2803-2806.
5. Zhou XC, Huang RC, Zhang B, Yin D, Liang B, Wang SP, et al. Inflammation inhibitory effects of sirolimus and paclitaxel-eluting stents on interleukin-1p-induced coronary artery in-stent restenosis in pigs. Chin Med J 2010; 123: 2405-2409.
6. Cook S, Ladich E, Nakazawa G, Eshtehardi P, Neidhart M, Vogel R, et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 2009; 120: 391-399.
7. Wilson GJ, Nakazawa G, Schwartz RS, Huibregtse B, Poff B, Herbst TJ, et al. Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries. Circulation 2009; 120: 141-149, 1-2.
8. Serruys PW, Onuma Y, Dudek D, Smits PC, Koolen J, Chevalier B, et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol 2011; 58: 1578-1588.
9. Byrne RA, Eberle S, Kastrati A, Dibra A, Ndrepepa G, Iijima R, et al. Distribution of angiographic measures of restenosis after drug-eluting stent implantation. Heart 2009; 95: 1572-1578.
10. Han Y, Jing Q, Chen X, Wang S, Ma Y, Liu H, et al. Long-term clinical, angiographic, and intravascular ultrasound outcomes of biodegradable polymer-coated sirolimus-eluting stents. Catheter Cardiovasc Interv 2008; 72: 177-183.
11. Li Y, Li CX, Wang HC, Xu B, Fang WY, Ge JB, et al. Efficacy and safety of Firebird sirolimus-eluting stent in treatment of complex coronary lesions in Chinese patients: one-year clinical and eight-month angiographic outcomes from the FIREMAN registry. Chin Med J 2011; 124: 817-824.
12. Mehran R, Dangas G, Abizaid AS, Mntz GS, Lansky AJ, Satler LF, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 1999; 100: 1872-1878.
13. Windecker S, Remondino A, Eberh FR, Jiini P, Räber L, Wenaweser P, et al. Sirolimus-elutmg and pachtaxel-eluting stents for coronary revascularization N Engl J Med 2005; 353: 653-662.
14. Nakazawa G, Finn AV, Vorpahl M, Ladich ER, Kolodgie FD, Virmani R. Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents. J Am Coll Cardiol 2011; 57: 390-398.
15. Han Y, Jing Q, Xu B, Yang L, Liu H, Shang X, et al. Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes. JACC Cardiovasc Interv 2009; 2: 303-309.
16. Chen SL, Xu T, Zhang JJ, Ye F, Hu ZY, Tian NL. Angioscopy study from a large patient population companng sirolimus-eluting stent with biodegradable versus durable polymer. Catheter Cardiovasc Interv 2012; 80: 420-428.
17. Barlis P, Regar E, Serruys PW, Dimopoulos K, van der Giessen WJ, van Geuns RJ, et al. An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. Eur Heart J 2010; 31: 165-176.
18. Hoffmann R, Guagliumi G, Musumeci G, Reimers B, Petronio AS, Disco C, et al. Vascular response to sirolimus-eluting stents delivered with a nonaggressive implantation technique: comparison of intravascular ultrasound results from the multicenter, randomized E-SIRIUS, and SIRIUS trials. Catheter Cardiovasc Interv 2005; 66: 499-506.
19. Liu HL, Jin ZG, Luo JP, Ma DX, Yang SL, Liu Y, et al. Long-term effects of biodegradable versus durable polymer-coated sirolimus-eluting stents on coronary arterial wall morphology assessed by virtual histology intravascular ultrasound. Chin Med J 2011; 124: 836-844.
20. Schofer J, Schlüter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003; 362: 1093-1099.
21. Wakabayashi K, Waksman R, Weissman NJ. Edge effect from drug-eluting stents as assessed with serial intravascular ultrasound: a systematic review. Circ Cardiovasc Interv 2012; 5: 305-331.
22. Tanabe K, Kishi S, Aoki J, Tammoto S, Onuma Y, Yachi S, et al. Impact of coronary calcium on outcome following sirolimus-eluting stent implantation. Am J Cardiol 2011; 108: 514-517.
23. Qian J, Xu B, Lansky AJ, Yang YJ, Qiao SB, Wu YJ, et al. First report of a novel ablummal groove filled biodegradable polymer rapamycm-eluting stent in de novo coronary artery disease: results of the first in man FIREHAWK trial. Chin Med J 2012; 125: 970-976.
24. Xu B, Dou KF, Han YL, Lil SZ, Yang YJ, Huo Y, et al. A prospective multicenter parallel-controlled trial of TIVOLI biodegradable-polymer-based sirolimus-eluting stent compared to ENDEAVOR zotarolimus-eluting stent for the treatment of coronary artery disease: 8-month angiographic and 2-year clinical follow-up results. Chin Med J 2011; 124: 811-816.